A case report of uveitis with ocular hypertension

Authors

  • N. V. Konovalova SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"; Odesa (Ukraine)
  • V. V. Savko SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"; Odesa (Ukraine)
  • N. I. Khramenko SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"; Odesa (Ukraine)
  • O. V. Guzun SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"; Odesa (Ukraine)
  • S. B. Slobodianyk SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"; Odesa (Ukraine)
  • Iu. A. Zhuravok SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"; Odesa (Ukraine)
  • V. V. Savko SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"; Odesa (Ukraine)

DOI:

https://doi.org/10.31288/oftalmolzh201967075

Keywords:

uveitis, ocular hypertension, prostaglandin analogues

Abstract

Based on a clinical case, we analyzed the characteristics of diagnosis, course, and treatment of uveitis in the presence of ocular hypertension.

References

1.Arbenyeva NS, Chekhova TA, Bratko GV, Chernakh VV. [Comparative analysis of diseases incidence in patients with uveitis]. [The Annual All-Russian Scientific Practical Conference of Young Scientists «Current Problems of Ophthalmology». Abstract book]. M.: Oftalmologiia; 2012: 28-29. In Russian

2.Drozdova EA. [The classification and epidemiology of uveitis]. RMZh. Klinicheskaia Oftalmologiia; 2016;3:155-9. In Russian.

3.Panova IE, Drozdova EA. [Uveitis: Guidance for practitioners]. M.: Meditsinskoie informatsionnoie agenstvo; 2014. 144p. In Russian.

4.Аnamori A, Naka M, Fukuda M et al. Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Exp. Eye Res. 2009;88(3):535-41 https://doi.org/10.1016/j.exer.2008.11.012

5.Asrani S, Moore DB, Jaffe GJ. Paradoxical changes of retinal nerve fiber layer thickness in uveitic glaucoma. JAMA Ophthalmology. 2014; 132(7): 877-80. https://doi.org/10.1001/jamaophthalmol.2014.954

6.Boltz A, Schmidl D, Weigert G et al. Effect of latanoprost on choroidal blood flow regulation in healthy subjects.Invest. Ophthalmol. Vis. Sci. 2011;52(7):4410-5.https://doi.org/10.1167/iovs.11-7263

7.Horsley MB, Chen TC. The use of prostaglandin analogs in the uveitis patient. Seminars in Ophthalmology. 2011;26(4-5):285-9.https://doi.org/10.3109/08820538.2011.588650

8.Kurashima H, Watabe H, Sato N et al. Effects of prostaglandin F(2?) analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost. Exp. Eye Res. 2010; 91(6):853-9.https://doi.org/10.1016/j.exer.2010.09.004

9.Markomichelakis NN, Kostakou A, Halkiadakis I, Chalkidou S, Papakonstantinou D, Georgopoulos G. Efficacy and safety of latanoprost in eyes with uveitis glaucoma. Graefe's Arch for Clin and Exp Ophthalmol. 2009;247(6):775-80.https://doi.org/10.1007/s00417-009-1036-3

10.Nakanishi Y, Nakamura M, Mukuno H et al. Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mutagen-activated protein kinas. Exp. Eye Res. 2006;83(5):1108-17.https://doi.org/10.1016/j.exer.2006.05.018

11.Takeuchi M, Kanda T, Taguchi M et al. Evaluation of Efficacy and Safety of Latanoprost/Timolol versus Travoprost/Timolol Fixed Combinations for Ocular Hypertension Associated with Uveitis. Ocul Immunol Inflamm. 2017; Feb 25 (1):105-10.https://doi.org/10.3109/09273948.2015.1092559

Downloads

Published

2025-12-11

How to Cite

[1]
Konovalova, N.V. et al. 2025. A case report of uveitis with ocular hypertension. Ukrainian Journal of Ophthalmology . 6 (Dec. 2025), 70–75. DOI:https://doi.org/10.31288/oftalmolzh201967075.

Issue

No. 6 (2019): Journal of Ophthalmology (Ukraine)

Section

Case Reports

License

Copyright (c) 2025 Н. В. Коновалова, В. В. Савко, Н. И. Храменко, О. В. Гузун, С. Б. Слободяник, Ю. А. Журавок, В. В. Савко

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.

COPYRIGHT NOTICE

Authors who publish in this journal agree to the following terms:

  1. Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
  2. The copyright commencement date complies the publication date of the issue, where the article is included in.

DEPOSIT POLICY

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
  3. Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
  4. Archiving the pre-print (pre-refereeing manuscript version) not allowed.

Similar Articles

You may also start an advanced similarity search for this article.